Key Takeaways
- In-line quarter, margin aberration: Revenue met expectations but gross margin fell sharply as two higher-margin products missed the quarter, a mix management calls a one-timer and not the new steady state.
- Growth is "preordained" for 2-3 years: Management says existing commercialized CMS molecules and capacity expansions lock in growth through FY27, requiring only execution, not new wins.
- Peptide bet enters show-me phase: The large-scale peptide facility commissions in July; the stated goal is at least one commercial peptide NCE arrangement in FY27, with the asset base now built and monetization the next step.
- Inventory build signals revenue ramp, not profit: Inventory rose sharply as a precursor to future shipments; management explicitly rejected linking the inventory increase to the PAT rise but offered no alternative profit driver.
- What to watch next quarter: Whether the CMS capacity ramp-up accelerates as guided, whether paliperidone shipments resume in FY27, and any concrete peptide partnership announcements.
Margin & Product Mix
- Two products drove the miss: One high-margin CMS product had zero shipments this quarter, and paliperidone, a higher-margin GDS specialty product, was delayed by operational issues at the customer end.
- CMS margin structure intact: Management affirmed the basic hypothesis that CMS margins are significantly higher than prime product gross margins; the quarter's softness was absence of a specific CMS product, not a structural shift.
- Product mix is the dominant margin driver: Gross margin this quarter is a function of product mix as the largest factor; the prior two to three quarters are a better representation of gross margins going forward.
- Operating leverage is lumpy by design: Larger individual CMS shipment values mean small operational or logistical changes can have an outsized impact on any single quarter's performance.
- Ezetimibe and Mirtazapine continue as key contributors to the prime GDS portfolio; Apixaban and Donepezil contributed on the specialty side.
- Management declined to guide gross margin trajectory over a 5-year horizon, and warned that product mix callouts ahead of time will be very hard to make, asking investors to evaluate on a 2-3 year period rather than quarter-on-quarter.
Davuluri: "What I can assure you is that the gross margin that you've seen in this quarter is more of an outlier or an aberration for multiple reasons that it is not a steady gross margin going forward."
CMS Ramp-Up & Capacity
- CMS capacity expansion completed: Additional volume capacity for a CMS product was finished and ramp-up has started, with volumes shipped in Q3, but the ramp-up is still very early.
- Ramp-up to take one to two more quarters: The expanded CMS capacity will take maybe another one or two quarters to really pick up.
- New CMS molecule commercialized: The additional CMS molecule discussed previously was commercialized; some shipments went out at the tail end of the quarter, but a lot remains to be done.
- More CMS commercializations expected: Management said the market will see a lot more molecules contribute over the next few quarters.
- New facility ramp-up has unknowns: The ramp-up of the new production facility is going well and is not delayed, but the timeline to hit full capacity has too many unknowns for management to pin down precisely.
- FY26-FY27 is the ramp-up window: Growth will be driven by previously commercialized CMS molecules, newly expanded capacity in Unit 3, and the additional CMS molecule just starting commercialization, all coming into formation over the next two to three quarters.
Davuluri: "I think maybe we should see as reaching full production soon, not just for the Unit 3 new facility, but for the other CDMO molecule as well. But I think there are too many unknowns that we are dealing with."
Inventory Build
- Inventory ramp-up is a revenue precursor: Inventory is being built to meet revenue expectations from customers in subsequent quarters; conversion to sales depends on production ability and other factors.
- Management rejected profit linkage: When an analyst noted PAT rose ~INR150 crores while inventory rose ~INR170 crores, management said the correlation is not correct and inventory should be correlated with future sales, not profit, but did not provide an alternative explanation for the PAT increase.
- Inventory days expanded: Management shifted the discussion from absolute figures to days perspective, noting inventory moved from 94 days to 124 days.
Pipeline & Commercial Portfolio
- Commercial molecule count stable, value rising: 19 commercial molecules with commercial APIs remaining at 9; value per molecule has gone up, which management says is the organization's intention.
- Engagement threshold raised: Five to seven years ago Neuland would engage with entrepreneurs with just an idea and no capital; today programs must be well-funded with at least a moderate chance of reaching the clinic.
- Pipeline actively curated: The number of projects appears similar to last year because management keeps the list active rather than inflating numbers; preclinical and Phase I projects came in last quarter.
- New commercial molecules added: One new molecule added in the API commercial segment and two molecules added in the intermediate commercial segment.
- New business deliveries are expected to happen over 12 to 24 months.
Peptides: The Next Growth Vector
- Facility commissioning in July: The large-scale peptide manufacturing facility will be ready for commissioning in July.
- New R&D campus for peptides: A new R&D campus in Genome Valley will create a modern process development and scale-up facility for peptides; combined with large-scale manufacturing capacity, management believes this creates a configuration probably not matched by many Indian CDMOs.
- FY27 commercial target: Management said it would be ideal to secure at least one commercial manufacturing arrangement for a peptide NCE in FY27, and that this is very much possible and being worked towards.
- Peptides as entry to big pharma: The endpoint into new big pharma relationships, with companies Neuland does not already work with, would be through peptides; still in conversation stage.
- Investment rationale: Conversations with innovators from 2022-2024 led to a firm belief that large-scale peptide manufacturing was a need, driven by GLP-1 and amylin analogues requiring more capacity, with Western world capacity saturated.
- Monetization plan: The next 2-3 years will be spent working aggressively to find peptide partnerships; capital is allocated and assets are built, now it is time to monetize those assets for growth in a 3-5 year period.
Davuluri: "When you have a good modern R&D setup for peptides, in our new campus in Genome Valley. And then you combine that with the newly created large-scale peptide manufacturing capacity, then we would have a configuration, which would probably not be matched by many Indian CDMOs."
Trade Policy & External Environment
- India-EU trade deal: Makes API procurement from India marginally more attractive for European pharma as costs become cheaper, but no material change is expected.
- US-India trade deal: No direct benefit since pharma has been exempt from tariffs; removes a small overhang, but the continued US intent to secure API manufacturing domestically is a concern to watch and strategize around.
- Management did not quantify any expected revenue or margin impact from either trade deal when asked.
Davuluri: "There seems to be a continued intent for the U.S. to secure API manufacturing in the U.S. And that's something that we'll have to still wait and watch. I think the U.S. India trade deal does not really alleviate that potential concern."
Long-Term Strategic Ambition
- Growth preordained for 2-3 years: Existing products lock in growth through FY27; the task is execution, not new business development.
- Decadal aspiration: From 2026 to 2036, management sees potential for 20-plus percent CAGR, but this requires a sequence of right plans to fall in place.
- Beyond peptides: After the 3-5 year peptide monetization window, the next white spaces may not be new modalities like oligonucleotides; they could be geographic expansion or building capabilities in the US or Europe.
- Business still in early growth phase: Ramp-ups are yet to begin; investments create opportunity for growth beyond the 3-4 year period.
- Organizational readiness: Management is upskilling people, expanding teams, designing teams for growth, and ensuring capital is available and deployed appropriately.
Davuluri: "I think if you look at 2026 to 2036 I think there is a potential for a business like this to grow at 20-plus CAGR, but that requires I think, a sequence of right plans to fall in place."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CMS capacity ramp-up | Expanded CMS capacity to pick up meaningfully | One to two quarters |
| Paliperidone resolution | Operational issues at customer end to resolve | Next financial year (FY27), not next quarter |
| Peptide facility commissioning | Large-scale peptide manufacturing facility ready | July |
| Peptide commercial arrangement | Secure at least 1 commercial manufacturing arrangement for a peptide NCE | FY27 (ideal target) |
| Growth delivery | Growth preordained by existing products; ramp-ups to show business potential | Next 2-3 quarters through FY27 |
| Gross margin normalization | This quarter is an outlier; prior 2-3 quarters are better representation | Going forward (no date) |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Total income | ₹447.8 cr, +11.4% YoY vs ₹401.9 cr |
| Commercial CMS revenue share | Over 50% of total revenue |
| Gross margin | An outlier/aberration this quarter, not a steady gross margin going forward; product mix was the largest factor |
| EBITDA margin (FY24 reference) | ~30% in FY24, business capable of 30% and higher |
| Net debt | Negative ₹202.6 cr (net cash position) |
| Capex (9M FY26) | ₹254 cr cash outflow |
| Free cash flow (FY26 to date) | Negative ₹9.2 cr, restricted by substantial customer advances |
| Inventory | ₹548 cr, up from ₹386 cr; inventory days at 124 days on current sales basis, up from 94 days in FY25 |
| CMS pipeline value | Several multi-hundred crore molecules in pipeline; first commercial CMS molecule was ~₹30 cr |
| Growth outlook | 20%+ CAGR potential from 2026 to 2036; next 2–3 years growth preordained by existing products |
| Peptide capacity | New large-scale peptide manufacturing capacity expected ready for commissioning in July (FY27) |
| New R&D campus | Board approved shifting R&D to a new campus in Genome Valley |
| Unit 3 capacity expansion | Completed; ramp-up started in Q3, expected to reach full production over next 1–2 quarters |
| New CMS molecule commercialization | Commercialized; some shipments at tail end of Q3, majority of ramp-up still ahead |
| Paliperidone shipment delay | Operational issues at customer end caused delay; resolution expected next financial year |